SAT-LB9 Anti-Cancer Properties of RISUG Against Prostrate Cancer Cell Line PC-3 -Invitro Study

• Published in: Journal of the Endocrine Society 2020-05, Vol.4 (Supplement_1)
• Main Authors: Singroul, Pankaj, Singh, Palak, Guha, Sujoy K, Gupta, Surabhi, Chaturvedi, Pradeep Kumar
• Format: Article
• Language: English
• Subjects: Reproductive Endocrinology
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvaa046.2019

Cancer cell lines were initially established for understanding the genetic, functional, and epigenetic properties of cancer cells. The PC3 cell line is a human-derived prostate cancer cell line from the metastatic bone site of the grade IV adenocarcinoma patient. With the invention of RISUG-a polymeric male contraceptive, and studying its astonishing properties such as anti-microbial activity, there have been multiple hypotheses stating its anti-cancerous effect based on its physical and chemical nature[1]. This study focuses on understanding the effect of RISUG on prostate cancer cell line PC3 via MTT assay.For our study, 10 mg/ml working concentration of RISUG in DMSO (solvent) was used for the treatment to the cells. The dosage given to the cells for three varying incubation periods of 24 hours, 48 hours and 72 hours were analyzed for there viable cells post treatment. The dose was delivered with the media such that the final concentration of DMSO in the media is 1.5% (optimized) to avoid vehicle toxicity. The MTT assay was employed to study the cytotoxicity effect by measuring the amount of viable cells post treatment. The observations were statistically significant for the anti-cancerous effect of RISUG on PC3 prostate cancer cells for 72 hours, the optimized minimum incubation time/ time of action for RISUG to exhibit significant anti-cancer effect against PC3 cells. However, further in depth research is necessary for the understanding of the mechanism behind these actions. Keywords: RISUG, Prostate Cancer, DMSO, Cell line, Reference: 1. Subramanian, B., Agarwal, T., Basak, P., Maiti, T., & Guha, S. (2019). RISUG® based improved intrauterine contraceptive device (IIUCD) could impart protective effects against development of endometrial cancer. Medical Hypotheses, 124, 67-71. doi: 10.1016/j.mehy.2019.02.026